about
Application of the DETECT algorithm for detection of risk of pulmonary arterial hypertension in systemic sclerosis: data from a Czech tertiary centre.Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status.Elective minimally invasive coronary artery bypass: shunt or tournique occlusion? Assessment of a protective role of perioperative left anterior descending shunting on myocardial damage. A prospective randomized studyVascular Endothelial Growth Factor Is Associated with the Morphologic and Functional Parameters in Patients with Hypertrophic CardiomyopathyHigh on-treatment platelet reactivity: risk factors and 5-year outcomes in patients with acute myocardial infarction.Current applications of cardiac troponin T for the diagnosis of myocardial damage.Severe bradycardia after a methylprednisolone "minipulse" treatment.Elevated cardiac markers are associated with higher mortality in patients after transjugular intrahepatic portosystemic shunt insertion.Long-term prognosis after out-of-hospital cardiac arrest with/without ST elevation myocardial infarction.Continuous 24-h monitoring of electrocardiogram during anthracycline-based therapy in acute leukemia.Chronic thromboembolic pulmonary hypertension after the first episode of pulmonary embolism? How often?NT-proBNP correlates not only with ejection fraction, but also with inferior vena cava diameter in patients with acute heart failure.Plasma concentration of fibronectin is decreased in patients with hypertrophic cardiomyopathy.Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge.Echocardiographic imaging of coronary artery abscess following stent implantation.Plasma glycogen phosphorylase BB is associated with pulmonary artery wedge pressure and left ventricle mass index in patients with hypertrophic cardiomyopathy.The prognostic significance of intermediate QRS prolongation in acute myocardial infarctionCytokines and adhesion molecules in the course of acute myocardial infarctionAnthracycline therapy can induce very early increase in QT dispersion and QTc prolongationNew biomarkers of myocardial injury and assessment of cardiac toxicity during preparative regimen and hematopoietic cell transplantation in acute leukemiaRe-expression of nestin in the myocardium of postinfarcted patientsGlycogen phosphorylase BB as a marker of cardiac toxicity during high-dose chemotherapy followed by hematopoietic cell transplantationGlycogen phosphorylase BB could be a new circulating biomarker for detection of anthracycline cardiotoxicityCardiac troponin I seems to be superior to cardiac troponin T in the early detection of cardiac injury associated with anthracycline treatmentHigh-sensitivity troponin T as a marker of myocardial injury after radiofrequency catheter ablationRoutine upfront abciximab versus standard periprocedural therapy in patients undergoing primary percutaneous coronary intervention for cardiogenic shock: The PRAGUE-7 Study. An open randomized multicentre studyGlycogen phosphorylase BB could be a new biomarker for detection of cardiac toxicity during hematopoietic cell transplantation for hematological malignanciesIncrease of serum interleukin 6 and interferon γ is associated with the number of impulses in patients with supraventricular arrhythmias treated with radiofrequency catheter ablationGlycogen phosphorylase BB levels are associated with haemodynamic parameters in cirrhotic patients undergoing transjugular intrahepatic portosystemic shunt insertion
P50
Q30990678-43C68DDF-9820-49C3-B093-97C2F3618736Q34399789-14C32514-DEA6-44E6-9CD7-2D2812C808F6Q36367690-9C361726-3063-4548-8AFA-EFF84C5C0781Q36529034-3FD277C8-605A-4026-B58F-FA309C3A0DF3Q37680302-51D7BB64-47D1-4C92-AA8A-F3CBF0B6F0D7Q38135427-1C7F35F8-74AE-42DE-87ED-A95A6910CA60Q43695884-3CB4BAB0-33DC-469A-98C7-9E21B871A0CDQ43975718-97F671AA-2328-46FA-80AD-984AD4B1EBB9Q46027652-4108E802-FF1D-4D3C-8D8D-C0C484469D03Q46112273-AF189EC4-8CE5-48BD-86FD-AB5E470703DEQ47568304-E735DDAE-5E61-42AB-871D-6E02B9698556Q48332205-91FFD935-1DC6-4184-8C72-9D5324B00BDFQ48442977-C470FA4D-343F-4106-A462-CD26323A3537Q49719570-14D24CE2-597B-4711-BF8D-999102EDA371Q51723442-39648E20-BF45-4FEB-88D9-D2789C799809Q55052917-187160FC-2821-4075-803A-AFF597E8EECCQ73934891-FB304031-2851-43A3-8572-D2B768B6886BQ74631883-667961EF-C761-43C4-96FE-17285A6818A8Q79831483-EB9E7466-AD6E-4084-B5F2-C25DB79536CCQ80490213-6C600E14-E40F-4489-B666-666CC907C46EQ81436318-AD07134A-4521-4BD3-B643-83E28DD7BDB4Q81533400-C2B2B772-0C21-46BB-BCA8-D1C366D0B6E3Q81630347-520FA2F0-AC4D-465D-BACB-5ECAD5B608DDQ82295093-A3FB303C-5AA5-4608-8F46-422C4F02456BQ82562309-8DDD71E7-299B-4274-A7E8-639444157456Q83990373-E0EA5A24-D786-49DE-B292-2ED5BB486928Q84866855-56C1BC42-6659-4AEF-A80B-F0C9155163CCQ86129708-A0F80973-BA65-4280-92A7-916073993681Q87781034-1A57F463-F127-444E-997C-0F088F8ED980
P50
description
kardiolog
@cs
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Radek Pudil
@ast
Radek Pudil
@cs
Radek Pudil
@en
Radek Pudil
@es
Radek Pudil
@nl
type
label
Radek Pudil
@ast
Radek Pudil
@cs
Radek Pudil
@en
Radek Pudil
@es
Radek Pudil
@nl
prefLabel
Radek Pudil
@ast
Radek Pudil
@cs
Radek Pudil
@en
Radek Pudil
@es
Radek Pudil
@nl
P214
P1153
6603088893
P214
P31
P496
0000-0002-4042-7100
P691
P7859
viaf-85553830